Skip to main content
. 2021 Feb 9;124(8):1411–1420. doi: 10.1038/s41416-021-01272-6

Fig. 2. PRIVIGEN® IgG impairs the cell-toxic effects of oxaliplatin.

Fig. 2

The indicated colon cancer cell lines were treated with sham, 6.25 µM oxaliplatin, 1.25 mg/mL, 2.50 mg/mL and 5 mg/mL PRIVIGEN® IgG, or the combination therapy (oxaliplatin plus IgG) for 1 day (a), 3 days (b) or 5 days (c). After 5 days, 6.25 µM OXA significantly inhibited cell viability, when compared to sham-treated cells; however, 5 mg/mL PRIVIGEN® IgG significantly reverted these toxic effects of oxaliplatin. The green dots indicate cells treated by sham, the red triangles indicate cells treated by oxaliplatin, the black dot indicates cells treated by IgG and the white dots indicate cells treated by oxaliplatin plus IgG. $ indicates P-values determined by Student t test; * indicates P-values determined by Mann–Whitney U test. N = 9 for (a–h); N = 8 for (l); N = 7 for (k); N = 6 for (i) and (j).